GNH USA

Europe — EMA

Natriumalendronat (Ph. Eur.) Dura (Alendronate Sodium Trihydrate)

GNH USA supplies Natriumalendronat (Ph. Eur.) Dura (Alendronate Sodium), a bisphosphonate for osteoporosis, Paget's disease and glucocorticoid‑induced bone

Alendronate Sodium Trihydrate

Request sourcing

1
Pack/s

What is Alendronate Sodium Trihydrate?

Alendronate sodium trihydrate, the active ingredient in Natriumalendronat (Ph. Eur.) Dura, is a bisphosphonate presented as a tablet for oral use. It is employed to treat conditions characterized by excessive bone resorption, such as osteoporosis, Paget's disease of bone, and glucocorticoid‑induced osteoporosis, primarily in post‑menopausal women and other at‑risk populations.

GNH USA supplies Natriumalendronat (Ph. Eur.) Dura as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Alendronate Sodium Trihydrate used for?

Alendronate sodium trihydrate acts on the skeletal system to reduce pathological bone turnover, making it useful for several bone‑related disorders. - Osteoporosis: improves bone mineral density and reduces fracture risk. - Paget's disease of bone: normalises abnormal bone remodeling. - Glucocorticoid‑induced osteoporosis: counteracts steroid‑related bone loss.

What are the side effects of Alendronate Sodium Trihydrate?

Alendronate sodium trihydrate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Gastrointestinal irritation: dyspepsia, abdominal pain, nausea. - Musculoskeletal pain: bone, joint or muscle aches. - Esophageal ulceration or irritation. - Transient flu‑like symptoms after the first dose. - Headache. - Skin rash or pruritus.

Serious or Rare Side Effects: - Osteonecrosis of the jaw (ONJ). - Atypical femoral fractures. - Severe esophageal ulceration or perforation. - Acute phase reactions with fever and myalgia. - Hypocalcaemia. - Severe allergic reactions (anaphylaxis).

What precautions apply to Alendronate Sodium Trihydrate?

Before initiating therapy, clinicians should assess patient suitability and monitor relevant parameters. - Renal function: evaluate creatinine clearance; avoid in severe impairment. - Calcium/Vitamin D status: ensure adequate supplementation to reduce hypocalcaemia risk. - Esophageal disorders: avoid in patients with active esophagitis or strictures. - Concomitant medications: review for drugs that may irritate the GI tract. - Pregnancy and lactation: use only if potential benefit outweighs risk; data are limited. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

What does Alendronate Sodium Trihydrate interact with?

Alendronate sodium trihydrate can interact with several agents, affecting absorption or safety.

Major Interactions (Avoid): - Calcium or multivitamin supplements taken within 30 minutes of the dose: markedly reduces absorption. - Antacids containing aluminum, magnesium, or calcium: impair oral bioavailability. - Proton pump inhibitors (PPIs): may increase risk of gastrointestinal adverse events.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of upper GI irritation. - Corticosteroids: synergistic effect on bone loss; monitor bone density. - Warfarin: occasional reports of altered INR; monitor coagulation parameters.

Frequently asked questions

What conditions is Natriumalendronat (Ph. Eur.) Dura used to treat?+
Natriumalendronat (Ph. Eur.) Dura contains alendronate sodium trihydrate, a bisphosphonate indicated for osteoporosis, Paget's disease of bone, and glucocorticoid‑induced osteoporosis. It helps strengthen bone and lower the risk of fractures in patients with increased bone turnover.
How does alendronate sodium trihydrate work in the body?+
Alendronate sodium trihydrate binds to hydroxyapatite on bone surfaces and is internalised by osteoclasts during resorption. It blocks the enzyme farnesyl pyrophosphate synthase in the mevalonate pathway, preventing prenylation of essential proteins, which reduces osteoclast activity and slows bone loss.
What is the usual dose of Natriumalendronat (Ph. Eur.) Dura?+
The specific dose of Natriumalendronat (Ph. Eur.) Dura is determined by the prescribing clinician based on the patient’s diagnosis, renal function, and other clinical factors. Healthcare professionals should follow local prescribing guidelines and adjust the regimen as needed.
Is Natriumalendronat (Ph. Eur.) Dura safe during pregnancy or breastfeeding?+
Safety data for alendronate sodium in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any possible risk to the fetus or infant. Clinicians should discuss risks and alternatives with pregnant or nursing patients.
How do I order Natriumalendronat (Ph. Eur.) Dura from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.
How does Natriumalendronat compare with other osteoporosis treatments?+
Alendronate sodium is a first‑line oral bisphosphonate, offering a well‑established efficacy profile for reducing vertebral and non‑vertebral fractures. Compared with newer agents such as denosumab or romosozumab, alendronate is generally less costly but requires strict administration rules (fasting, upright posture) to minimise gastrointestinal irritation.
What are the recommended storage conditions for Natriumalendronat (Ph. Eur.) Dura?+
Store the tablets at temperatures below 25 °C in their original blister pack. Protect them from moisture, excessive heat and direct sunlight to maintain potency throughout the shelf‑life.
How should Natriumalendronat (Ph. Eur.) Dura be taken?+
The tablet should be taken with a full glass of plain water on an empty stomach, at least 30 minutes before the first food, beverage, or other medication of the day. Remain upright for at least 30 minutes after ingestion to reduce the risk of esophageal irritation.
What are the most serious risks associated with Natriumalendronat (Ph. Eur.) Dura?+
Serious adverse events include osteonecrosis of the jaw, atypical femoral fractures, severe esophageal ulceration or perforation, and acute phase reactions such as fever and myalgia. Patients should report persistent jaw pain, unusual thigh or groin pain, or any signs of severe gastrointestinal distress promptly.
Who should not use Natriumalendronat (Ph. Eur.) Dura?+
The drug is contraindicated in patients with known hypersensitivity to alendronate or other bisphosphonates, those with severe renal impairment (creatinine clearance <30 mL/min), and individuals with active esophageal disorders such as ulceration or stricture. Caution is also advised for patients with low calcium levels.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Alendronate Sodium Trihydrate
Route
Oral Use
Manufacturer
Mylan Germany Gmbh
Origin
EU

Related products

Acide Alendronique Alter

Acide Alendronique Alter

Alendronate Sodium Trihydrate

Laboratoires Alter
EU
Acide Alendronique Arrow Lab

Acide Alendronique Arrow Lab

Alendronate Sodium Trihydrate

Arrow Generiques
EU
Acide Alendronique Cristers

Acide Alendronique Cristers

Alendronate Sodium Trihydrate

Cristers
EU
Acide Alendronique Cristers

Acide Alendronique Cristers

Alendronate Sodium Trihydrate

Cristers
EU